AOD-9604 dosing schedule female guide covering typical 250–500 mcg daily protocols, timing, reconstitution, and safety. AOD-9604 is not FDA-approved.
There is no FDA-approved AOD-9604 dosing schedule for women. In research and community settings, most female protocols run 250–500 mcg per day, injected subcutaneously once daily in the morning while fasted, typically 5–6 days a week for 8–12 weeks. AOD-9604 is not approved for human use in the United States, so every schedule circulating online is experimental rather than clinical guidance.
What AOD-9604 Actually Is
AOD-9604 is a synthetic peptide based on the C-terminal fragment of human growth hormone, amino acids 176–191. It was developed to study fat metabolism without the blood sugar and IGF-1 effects associated with full growth hormone.
Human trials used doses near 1 mg per day. Most online protocols use far less, and that gap between trial data and community practice is the main reason dosing advice varies so much.
Typical AOD-9604 Dosing Schedule for Women
Almost everyone who follows an aod 9604 dosage protocol starts low and adjusts based on tolerance. A 250 mcg starting dose is common, with 300–500 mcg used by people who report no side effects.
| Parameter | Common range | Notes |
|---|---|---|
| Daily dose | 250–500 mcg | Human trials used about 1 mg per day |
| Injection frequency | 1–2 per day | Short half-life leads some to split doses |
| Timing | Morning, fasted | Wait 20–30 minutes before eating |
| Days per week | 5–6 | Many use 5 days on, 2 days off |
| Cycle length | 8–12 weeks | Usually followed by about 4 weeks off |
| Route | Subcutaneous | Abdomen is common; rotate sites |
Doses are not weight-based in any published protocol. A 130-pound woman and a 220-pound woman are usually given the same instructions, even though body composition affects how a peptide behaves.
Do Women Need a Different Dose Than Men?
There is no published female-specific AOD-9604 dosing data. Sex differences in fat distribution, estrogen signaling, and growth hormone release are well documented, but no trial has translated them into a dosing recommendation.
One aod 9604 dosing schedule female users describe online is 250 mcg once daily for the first two weeks, then 300–500 mcg if it is tolerated. That is community convention, not evidence.
With no female-specific data, any dose a woman chooses is a guess informed by other people's anecdotes rather than by trials conducted in women.
How to Reconstitute AOD-9604 Without Gelling
AOD-9604 ships as a lyophilized powder and must be mixed with bacteriostatic water. To reconstitute aod 9604, drip the water slowly down the inside wall of the vial instead of spraying it directly onto the powder.
Shaking the vial or blasting the powder with a fast stream of water is the usual reason people see aod-9604 gelling up into clumps that never fully dissolve. Swirl gently, let it sit, and refrigerate the mixed vial at 2–8°C, protected from light.
Common reconstitution math
- 5 mg vial (5,000 mcg) + 2 mL bacteriostatic water = 2,500 mcg/mL
- 0.1 mL = 250 mcg
- 0.2 mL = 500 mcg
Timing, Stacking, and Comparisons
When to inject
Most schedules call for a fasted morning injection, followed by a 20–30 minute wait before eating. AOD-9604 has a short half-life, so some people split the daily dose into two smaller injections.
Stacking with tirzepatide
No human studies have combined AOD-9604 with tirzepatide. Tirzepatide is a prescription medication with its own risk profile, and stacking an unapproved research peptide on top of it is not something a clinician can dose safely from existing data.
AOD-9604 vs MOTS-c
The comparison of aod 9604 vs mots-c comes up often because both are marketed for metabolic and fat-loss goals. MOTS-c is a mitochondrial-derived peptide studied for exercise and insulin-related effects, so the two rely on different proposed mechanisms. Neither is FDA-approved for human use.
What user reviews say
User-written reviews of AOD-9604 describe modest, inconsistent fat loss, occasional injection-site irritation, and results that are hard to separate from diet and training. These reports are anecdotal and should not be used to set a dose.
Safety, Side Effects, and Legal Status
AOD-9604 is not FDA-approved for human use in the United States. Products sold for research purposes only are not verified for purity, sterility, or actual peptide content, and people who purchase AOD-9604 peptide products online have no way to confirm what is in the vial.
Reported side effects include redness or swelling at the injection site, headache, nausea, and joint discomfort. Rapid clearance does not make an unapproved peptide safe, and long-term human safety data is limited.
Talk with a licensed healthcare professional before using AOD-9604, especially if you are pregnant, breastfeeding, taking diabetes medication, or managing a thyroid condition.
Frequently Asked Questions
What is a typical AOD-9604 dosage for women?
Most community protocols use 250–500 mcg per day, injected subcutaneously once daily in the morning while fasted. Human clinical trials used closer to 1 mg per day, and no female-specific dose has ever been published. AOD-9604 is not FDA-approved, so any number is experimental.
How long do you run AOD-9604 before taking a break?
Most protocols run 8–12 weeks and then take about 4 weeks off. Some people inject 5 days a week with 2 days off instead. No study has tested whether cycling lowers risk, because long-term human data is limited.
Is AOD-9604 FDA-approved for weight loss?
No. AOD-9604 is not FDA-approved for any human use, including weight loss. It is sold as a research chemical, which means purity and sterility are not regulated. Anyone considering it should speak with a healthcare professional first.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.